Everest Organics FY26 Results: Net profit turns positive at ₹554.65 lakh

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights
  • Net profit turned positive to ₹554.65 lakh in FY26, reversing a ₹129.03 lakh loss
  • Revenue grew 23% YoY to ₹19,615.77 lakh driven by operational improvements
  • PBDIT more than doubled to ₹2,105.72 lakh, indicating strong margin expansion
  • Board retained earnings without recommending a dividend for FY26
  • Statutory auditors raised concerns over TSPCB production capacity compliance
powered bylight_fuzz_icon
50414048

*this image is generated using AI for illustrative purposes only.

Everest Organics returned to profitability in FY26, reporting a net profit of ₹554.65 lakh against a net loss of ₹129.03 lakh in the previous year. The company also announced that its 33rd Annual General Meeting (AGM) will be held on September 30, 2026.

Revenue from operations grew 23% to ₹19,615.77 lakh, up from ₹15,947.90 lakh in FY25. This top-line expansion was accompanied by a significant improvement in operating efficiency, with profit before financial cost, depreciation, and tax (PBDIT) more than doubling to ₹2,105.72 lakh from ₹790.98 lakh.

Financial Performance

The turnaround in profitability was driven by higher revenue and improved cost absorption. While finance costs increased to ₹652.76 lakh from ₹518.99 lakh, the overall operational gains outweighed these expenses. Earnings per share (EPS) stood at ₹5.70 for the year.

Metric FY26 FY25 Change
Revenue from Operations ₹19,615.77 lakh ₹15,947.90 lakh +23%
Net Profit ₹554.65 lakh (₹129.03 lakh) Turnaround
PBDIT ₹2,105.72 lakh ₹790.98 lakh +166%
EPS ₹5.70 (₹2.97) Positive

What the Numbers Show

The divergence between revenue growth and margin expansion highlights improved operational leverage. Revenue rose by approximately ₹3,668 lakh, while total expenses grew by only ₹2,596 lakh. This indicates that the additional revenue generated contributed disproportionately to the bottom line, allowing the company to cover fixed costs more effectively and reverse the prior year's loss.

Governance and Regulatory Updates

The Board did not recommend a dividend for FY26, opting instead to retain earnings to strengthen the balance sheet. Reserves and surplus increased to ₹6,576.77 lakh.

The AGM agenda includes the ratification of remuneration for cost auditors and the appointment of three new independent directors: Mr. Venkata Ramana Narra, Mr. Srikanth Reddy Kolli, and Mr. Subroto Banerjee. Remote e-voting will be open from September 27 to September 29, 2026.

Auditor Qualifications

The statutory auditors issued a qualified opinion regarding environmental compliance. The Telangana State Pollution Control Board (TSPCB) has stipulated that the company cannot exceed its approved production capacity. Management stated that applications for Consent for Establishment (CFE) for enhanced capacities are pending approval, though an Environmental Clearance Certificate has been obtained.

Historical Stock Returns for Everest Organics

1 Day5 Days1 Month6 Months1 Year5 Years
-0.81%-2.17%-10.52%-12.52%-31.95%-17.38%

How might the pending approval for Consent for Establishment (CFE) impact Everest Organics' ability to scale production and sustain its current revenue growth trajectory?

What specific operational strategies or cost-control measures are driving the significant improvement in PBDIT margins, and are these gains sustainable in the near term?

Given the decision to retain earnings rather than pay dividends, what is management's roadmap for utilizing these reserves to strengthen the balance sheet or fund future expansion?

Everest Organics Q1 Results: Net profit falls 20% YoY to ₹111.34 lakh

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights

Everest Organics posted a net profit of ₹111.34 lakh in Q1FY27, down 20.8% YoY, as revenue slipped 10% to ₹4,843.06 lakh. Pre-tax profits declined more sharply at 29.4%, signaling margin compression. Reserves grew to ₹6,688.11 lakh, while equity capital remained stable at ₹971.05 lakh.

powered bylight_fuzz_icon
48494630

*this image is generated using AI for illustrative purposes only.

Everest Organics reported a net profit of ₹111.34 lakh for the quarter ended June 30, 2026, marking a decline from the ₹140.52 lakh recorded in the corresponding period of FY25. Revenue from operations for Q1FY27 stood at ₹4,843.06 lakh, compared to ₹5,381.32 lakh in Q1FY25.

The company’s net profit before tax (PBT) decreased to ₹152.84 lakh in the current quarter, down from ₹216.43 lakh a year ago. Earnings per share (EPS), both basic and diluted, fell to ₹1.15 per share, lower than the ₹1.45 reported in Q1FY25.

Financial Performance

The Board of Directors approved the unaudited standalone financial results at a meeting held on August 14, 2026. The results have been reviewed by the Audit Committee and are subject to a limited review report by the auditors.

Metric: Q1FY27 Q1FY26 Change
Revenue from Operations: ₹4,843.06 lakh ₹5,381.32 lakh -10.0%
Net Profit Before Tax: ₹152.84 lakh ₹216.43 lakh -29.4%
Net Profit After Tax: ₹111.34 lakh ₹140.52 lakh -20.8%
EPS (Basic/Diluted): ₹1.15 ₹1.45 -20.7%

Balance Sheet Position

As of June 30, 2026, Everest Organics’ reserves increased to ₹6,688.11 lakh, up from ₹6,164.15 lakh in the same period last year. Equity share capital remained unchanged at ₹971.05 lakh. Total comprehensive income attributable to owners was ₹111.34 lakh, consistent with the net profit for the period.

What the Numbers Show

The divergence between revenue and profit declines highlights margin pressure during the quarter. While revenue contracted by approximately 10%, pre-tax profits fell nearly 30%, indicating that cost structures did not adjust proportionately to the lower top-line growth. This compression in operating efficiency is reflected in the wider gap between the PBT and PAT figures compared to the prior year.

Historical Stock Returns for Everest Organics

1 Day5 Days1 Month6 Months1 Year5 Years
-0.81%-2.17%-10.52%-12.52%-31.95%-17.38%

What specific cost drivers contributed to the disproportionate 29.4% drop in PBT compared to the 10% revenue decline, and are these costs structural or temporary?

How does Everest Organics plan to address the margin compression observed in Q1FY27 to restore profitability growth in subsequent quarters?

Are there any strategic initiatives or product mix changes planned to reverse the revenue contraction trend seen in the quarter ended June 30, 2026?

More News on Everest Organics

1 Year Returns:-31.95%